Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
Posted in | Nanomedicine | Nanobusiness

NanoBio CEO to Present Nanoemulsion-Based Adjuvant Platform Studies During World Influenza Congress

Published on December 7, 2009 at 6:59 PM

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium. The presentation details are as follows:

Dr. Baker will discuss the mechanisms of action and key characteristics of intranasal nanoemulsion-adjuvanted vaccines, and will share additional data demonstrating:

  • The nanoemulsion adjuvant's uptake into dendritic cells and generation of Th1-biased immunity without inducing an inflammatory response;
  • The efficacy of nanoemulsion-adjuvanted intranasal influenza vaccines in ferret models;
  • The efficacy of nanoemulsion-based adjuvants in subcutaneous and intramuscular models;
  • The safety results from NanoBio's ongoing Phase 1 clinical study of NB-1008, a nanoemulsion-adjuvanted seasonal influenza vaccine administered by nasal dropper.

Oral Presentation: Triggering Robust Immune Responses through Nanoemulsion-based Intranasal Vaccine Adjuvants
Date: Wednesday, December 9 at 10:05 a.m.
Location: Hilton Brussels Hotel, Belgium

Dr. Baker will also be a featured speaker in a panel session titled, "How can we develop strategies to maximize chances of approval for novel adjuvants?" on Wednesday, Dec. 9 at 11:30 a.m.

NanoBio's nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The company's NanoStat adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.

NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat technology platform. The company's lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), tinea capitis, acne, molluscum contagiosum, and cystic fibrosis. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan. NanoBio is a spin-off from the University of Michigan and holds the exclusive global license to the nanoemulsion platform technology.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit